Hjermstad M J, Fossa S D, Bjordal K, Kaasa S
Norwegian Cancer Society/Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
J Clin Oncol. 1995 May;13(5):1249-54. doi: 10.1200/JCO.1995.13.5.1249.
The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) is a well-validated instrument that assesses health-related quality of life (HRQOL) in cancer patients. It is used in cancer clinical trials in Europe, Canada, and the United States, and has demonstrated high reliability and validity in different groups of cancer patients. Despite thorough testing of reliability and validity, we have not identified any reports on its test/retest reliability; thus, a test/retest study was performed at the Norwegian Radium Hospital (NRH).
Cancer patients from the outpatient clinic who were off treatment for > or = 3 months were eligible for the study. The EORTC QLQ-C30 was given to the patients when they presented for their visit. The second questionnaire was received by the patients 4 days later. Of 291 eligible patients, 270 (93%) agreed to participate and 190 (73%) completed both questionnaires.
The test/retest reliability measured by Pearson's correlation coefficient was high for all functional scales, with a range from .82 for cognitive and role function to .91 for physical function. The r value for global HRQOL was .85. For the symptom scales--nausea/vomiting, fatigue, and pain--the coefficients were .63, .83, and .86, respectively. The single-item coefficients ranged from .72 for diarrhea to .84 for financial impact. The Spearman rank correlation was in the same range for all dimensions.
The EORTC QLQ-C30 seems to yield high test/retest reliability in patients with various cancer diagnoses whose condition is not expected to change during the time of measurement.
欧洲癌症研究与治疗组织核心生活质量问卷（EORTC QLQ-C30）是一种经过充分验证的工具，用于评估癌症患者的健康相关生活质量（HRQOL）。它在欧洲、加拿大和美国的癌症临床试验中使用，并已在不同组别的癌症患者中证明具有高可靠性和有效性。尽管对其可靠性和有效性进行了全面测试，但我们尚未发现任何关于其重测信度的报告；因此，在挪威镭医院（NRH）进行了一项重测研究。
门诊接受治疗≥3个月的癌症患者符合本研究条件。患者就诊时发放EORTC QLQ-C30问卷。4天后患者收到第二份问卷。在291名符合条件的患者中，270名（93%）同意参与，190名（73%）完成了两份问卷。
所有功能量表通过Pearson相关系数测量的重测信度都很高，认知和角色功能量表的相关系数为0.82，身体功能量表的相关系数为0.91。总体HRQOL的r值为0.85。对于症状量表——恶心/呕吐、疲劳和疼痛——相关系数分别为0.63、0.83和0.86。单项相关系数从腹泻的0.72到经济影响的0.84不等。所有维度的Spearman等级相关性在同一范围内。
对于在测量期间病情预计不会发生变化的各种癌症诊断患者，EORTC QLQ-C30似乎具有较高的重测信度。
